- MarketWatch•14 days ago
The federal government estimates that by 2020, mental and substance abuse disorders will surpass physical disease as a major cause of disability globally. Opiant Pharmaceuticals CEO Dr. Roger Crystal and ...
- GlobeNewswire•last monthOpiant Pharmaceuticals to Present at the Rodman & Renshaw Conference on September 13 in New York City
SANTA MONICA, Calif., Aug. 18, 2016-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, will present ...
- Accesswire•last month
NEW YORK, NY / ACCESSWIRE / August 15, 2016 / If you took NIH funding and got a drug approved by the FDA in the last 3 years, you are part of an elite group of 4 small-cap publicly-traded biotech names ...
Opiant Pharmaceuticals, Inc. (OPNT)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||8.10 - 8.73|
|52wk Range||7.03 - 8.89|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.94|
|Avg Vol (3m)||5,760|
|Dividend & Yield||N/A (N/A)|